TY - JOUR
T1 - Minocycline safety and tolerability in huntington disease
AU - Huntington study group
AU - Cha, Jang Ho
AU - Cudkowicz, Merit E.
AU - Gevorkian, Sona
AU - Young, Anne
AU - De Blieck, Elisabeth A.
AU - Kieburtz, Karl
AU - Marshall, Frederick
AU - Oakes, David
AU - Aileen Shinaman, M.
AU - Shoulson, Ira
AU - Zhao, Hongwei
AU - Friedlander, Robert
AU - Walker, Francis
AU - Hunt, Vicki
AU - Martin, Wayne
AU - Wieler, Marguerite
AU - Caviness, John
AU - Bernstein, Susan
AU - Anderson, Karen
AU - Weiner, William
AU - Dustin, Kelly
AU - Rosas, Diana
AU - Skeuse, Colleen
AU - Lausier, Martha
AU - Qureshi, Muhammad M.
AU - Biglan, Kevin
AU - Como, Peter
AU - Zimmerman, Carol
AU - Paulson, Henry
AU - Niehus, Kathryn
AU - Jennings, Danna
AU - Caplan, Karen
AU - Macdonald, Marcy
AU - Bean, Stephen
AU - De Blieck, Elisabeth A.
AU - Marshall, Frederick
AU - Orme, Constance
AU - Preston, Larry
AU - Weaver, Christine
AU - Winebrenner, Tina
AU - Bourgeois, Keith
AU - Watts, Arthur
AU - Zhao, Hongwei
N1 - Funding Information:
Supported primarily by a grant from the Food and Drug Administration Office of Orphan Products Development (FD-R-001968) and by grants from the Huntington Disease Society of America (New York) and the Hereditary Disease Foundation (Los Angeles, CA). Study drug and matching placebo were provided by Wyeth Pharmaceuticals (Collegeville, PA) and packaged and distributed by Stephen Bean, RPh (Investigational Drug Service Pharmacy, University of Rochester, NY).
Publisher Copyright:
© 2004 by AAN Enterprises, Inc.
PY - 2004/8/10
Y1 - 2004/8/10
N2 - Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.
AB - Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.
UR - http://www.scopus.com/inward/record.url?scp=3543092682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3543092682&partnerID=8YFLogxK
U2 - 10.1212/01.WNL.0000133403.30559.FF
DO - 10.1212/01.WNL.0000133403.30559.FF
M3 - Article
C2 - 15304592
AN - SCOPUS:3543092682
SN - 0028-3878
VL - 63
SP - 547
EP - 549
JO - Neurology
JF - Neurology
IS - 3
ER -